Successful topical treatment of anal giant condylomata acuminata in an infant.

Abstract

Anogenital condylomata acuminata are induced by human papillomavirus (HPV) and they rarely manifest in immunocompetent children. Therapeutic options depend on patient's age and general conditions and extension of the lesions. However, management is still a challenge and recurrences are frequent. Cryotherapy, laser, and surgical treatments in children are painful and frequently require general anesthesia. Imiquimod is a topical immune response modifier and constitutes a noninvasive alternative for the treatment of anogenital condylomata acuminata. Here, we report an infant admitted to our hospital with a giant vegetative papillomatous lesion on the perianal region surrounded by small satellites papules. PCR for HPV confirmed the clinical diagnosis of giant condylomata acuminata due to HPV type 6. The child has been successfully treated with topical 5% imiquimod cream without side effects. Although topical imiquimod is not licensed for pediatric age, this report highlights the potential benefits of its use in selected pediatric cases.

• Authors: Simona Giancristoforo, Andrea Diociaiuti, Hyppolite K Tchidjou, Maria Chiara Lucchetti, Claudia Carnevale, Roberta Rotunno, Patrizia D'Argenio, Maya El Hachem
• Journal: Dermatologic therapy (Dermatol Ther) Vol. 33 Issue 4 Pg. e13624 (07 2020) ISSN: 1529-8019 [Electronic] United States
• PMID: 32431022 (Publication Type: Journal Article)
• Copyright: © 2020 Wiley Periodicals LLC.

Chemical References

• Aminoquinolines
• Imiquimod

Topics

• Administration, Topical
• Aminoquinolines (therapeutic use)
• Child
• Condylomata Acuminata (diagnosis, drug therapy)
• Humans
• Imiquimod (therapeutic use)
• Infant
• Neoplasm Recurrence, Local